ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia - PubMed (original) (raw)
. 2004 Aug 26;351(9):893-901.
doi: 10.1056/NEJMoa040857.
Lang Huynh, Tracy L Toy, Liguang Chen, Michael J Keating, John G Gribben, Donna S Neuberg, Ian W Flinn, Kanti R Rai, John C Byrd, Neil E Kay, Andrew Greaves, Arthur Weiss, Thomas J Kipps
Affiliations
- PMID: 15329427
- DOI: 10.1056/NEJMoa040857
Free article
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
Laura Z Rassenti et al. N Engl J Med. 2004.
Free article
Abstract
Background: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV(H)) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV(H) but lack expression of ZAP-70.
Methods: We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV(H) gene. We then investigated the association between the results and the time from diagnosis to initial therapy.
Results: We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV(H) gene (71 percent), but in only 24 of the 143 patients with a mutated IgV(H) gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV(H) gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV(H) gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV(H) genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV(H) gene and 7.1 years in those with an unmutated IgV(H) gene (P<0.001).
Conclusions: Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.
Copyright 2004 Massachusetts Medical Society
Comment in
- Predicting Progression--ZAP-70 in CLL.
Hamblin TJ. Hamblin TJ. N Engl J Med. 2004 Aug 26;351(9):856-7. doi: 10.1056/NEJMp048184. N Engl J Med. 2004. PMID: 15329421 No abstract available.
Similar articles
- ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. Crespo M, et al. N Engl J Med. 2003 May 1;348(18):1764-75. doi: 10.1056/NEJMoa023143. N Engl J Med. 2003. PMID: 12724482 - Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M. Sheikholeslami MR, et al. Cytometry B Clin Cytom. 2006 Jul 15;70(4):270-5. doi: 10.1002/cyto.b.20134. Cytometry B Clin Cytom. 2006. PMID: 16906585 - Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, Tort F, Bosch F, López-Guillermo A, Colomer D, Montserrat E, Campo E. Carreras J, et al. J Pathol. 2005 Mar;205(4):507-13. doi: 10.1002/path.1727. J Pathol. 2005. PMID: 15685592 - Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
Bosch F, Muntañola A, Giné E, Carrió A, Villamor N, Moreno C, Crespo M, Montserrat E. Bosch F, et al. Cytometry B Clin Cytom. 2006 Jul 15;70(4):214-7. doi: 10.1002/cyto.b.20131. Cytometry B Clin Cytom. 2006. PMID: 16906580 Review. - The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia.
Kipps TJ. Kipps TJ. Best Pract Res Clin Haematol. 2007 Sep;20(3):415-24. doi: 10.1016/j.beha.2007.04.001. Best Pract Res Clin Haematol. 2007. PMID: 17707830 Review.
Cited by
- Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
Shao Q, Wykretowicz J, Hu N, Bedi K, Rizk M, Malek IA, Kumar S, Lombard DB, Shedden K, Scott D, Malek SN. Shao Q, et al. Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02448-8. Online ahead of print. Leukemia. 2024. PMID: 39455853 - Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia.
Kashyap MK, Karathia H, Kumar D, Vera Alvarez R, Forero-Forero JV, Moreno E, Lujan JV, Amaya-Chanaga CI, Vidal NM, Yu Z, Ghia EM, Lengerke-Diaz PA, Achinko D, Choi MY, Rassenti LZ, Mariño-Ramírez L, Mount SM, Hannenhalli S, Kipps TJ, Castro JE. Kashyap MK, et al. Mol Ther Nucleic Acids. 2024 Apr 26;35(2):102202. doi: 10.1016/j.omtn.2024.102202. eCollection 2024 Jun 11. Mol Ther Nucleic Acids. 2024. PMID: 38846999 Free PMC article. - An overview of prognostic markers in patients with CLL.
Braish J, Cerchione C, Ferrajoli A. Braish J, et al. Front Oncol. 2024 May 16;14:1371057. doi: 10.3389/fonc.2024.1371057. eCollection 2024. Front Oncol. 2024. PMID: 38817892 Free PMC article. Review. - Identification and Functional Investigation of Hub Genes Associated with Follicular Lymphoma.
Zhu Y, Jin X, Liu J, Yang W. Zhu Y, et al. Biochem Genet. 2024 May 27. doi: 10.1007/s10528-024-10831-4. Online ahead of print. Biochem Genet. 2024. PMID: 38802691 - CLLU1 as an emerging biomarker in chronic lymphoid leukemia.
Rong C, Liang C, Shen J, Zhang Y, Wang Q, Yang F, Chen Y, Luo Y, Gu M, Gao P, Xia Y, Duan S. Rong C, et al. Hum Cell. 2024 May;37(3):625-632. doi: 10.1007/s13577-024-01051-4. Epub 2024 Mar 20. Hum Cell. 2024. PMID: 38507118 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials